VANDA PHARMACEUTICALS INC (VNDA) Fundamental Analysis & Valuation

NASDAQ:VNDA • US9216591084

Current stock price

7 USD
-0.07 (-0.99%)
At close:
7 USD
0 (0%)
After Hours:

This VNDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. VNDA Profitability Analysis

1.1 Basic Checks

  • In the past year VNDA has reported negative net income.
  • VNDA had a negative operating cash flow in the past year.
  • In multiple years VNDA reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: VNDA reported negative operating cash flow in multiple years.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • VNDA has a Return On Assets (-45.09%) which is in line with its industry peers.
  • VNDA's Return On Equity of -67.38% is in line compared to the rest of the industry. VNDA outperforms 55.13% of its industry peers.
Industry RankSector Rank
ROA -45.09%
ROE -67.38%
ROIC N/A
ROA(3y)-15.86%
ROA(5y)-8.2%
ROE(3y)-23.48%
ROE(5y)-12.53%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • With an excellent Gross Margin value of 93.96%, VNDA belongs to the best of the industry, outperforming 94.97% of the companies in the same industry.
  • In the last couple of years the Gross Margin of VNDA has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.28%
GM growth 5Y0.74%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. VNDA Health Analysis

2.1 Basic Checks

  • VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VNDA has been increased compared to 1 year ago.
  • VNDA has more shares outstanding than it did 5 years ago.
  • VNDA has a worse debt/assets ratio than last year.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • VNDA has an Altman-Z score of 0.32. This is a bad value and indicates that VNDA is not financially healthy and even has some risk of bankruptcy.
  • VNDA's Altman-Z score of 0.32 is fine compared to the rest of the industry. VNDA outperforms 60.73% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that VNDA is not too dependend on debt financing.
  • The Debt to Equity ratio of VNDA (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.32
ROIC/WACCN/A
WACC9.22%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 2.39 indicates that VNDA has no problem at all paying its short term obligations.
  • VNDA has a Current ratio of 2.39. This is in the lower half of the industry: VNDA underperforms 71.76% of its industry peers.
  • VNDA has a Quick Ratio of 2.38. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of VNDA (2.38) is worse than 69.44% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.38
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. VNDA Growth Analysis

3.1 Past

  • VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -462.50%.
  • The Revenue has grown by 8.72% in the past year. This is quite good.
  • Measured over the past years, VNDA shows a decrease in Revenue. The Revenue has been decreasing by -2.73% on average per year.
EPS 1Y (TTM)-462.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
Revenue 1Y (TTM)8.72%
Revenue growth 3Y-5.29%
Revenue growth 5Y-2.73%
Sales Q2Q%7.58%

3.2 Future

  • VNDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.51% yearly.
  • The Revenue is expected to decrease by -2.33% on average over the next years.
EPS Next Y-39.4%
EPS Next 2Y25.42%
EPS Next 3Y26.51%
EPS Next 5YN/A
Revenue Next Year17.79%
Revenue Next 2Y27.22%
Revenue Next 3Y27.17%
Revenue Next 5Y-2.33%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. VNDA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VNDA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VNDA's earnings are expected to grow with 26.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.42%
EPS Next 3Y26.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VNDA Dividend Analysis

5.1 Amount

  • No dividends for VNDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VNDA Fundamentals: All Metrics, Ratios and Statistics

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (4/2/2026, 8:00:33 PM)

After market: 7 0 (0%)

7

-0.07 (-0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-05
Inst Owners69.95%
Inst Owner Change-3.25%
Ins Owners8.71%
Ins Owner Change12.09%
Market Cap413.77M
Revenue(TTM)216.10M
Net Income(TTM)-220.47M
Analysts80
Price Target15.81 (125.86%)
Short Float %6.07%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.89%
Min EPS beat(2)17.82%
Max EPS beat(2)65.96%
EPS beat(4)3
Avg EPS beat(4)18.8%
Min EPS beat(4)-26.44%
Max EPS beat(4)65.96%
EPS beat(8)6
Avg EPS beat(8)-3.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.73%
Min Revenue beat(2)-6.09%
Max Revenue beat(2)-5.37%
Revenue beat(4)1
Avg Revenue beat(4)-2.08%
Min Revenue beat(4)-6.09%
Max Revenue beat(4)8.7%
Revenue beat(8)2
Avg Revenue beat(8)-1.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.73%
PT rev (3m)31.91%
EPS NQ rev (1m)0.23%
EPS NQ rev (3m)-67.58%
EPS NY rev (1m)-69.95%
EPS NY rev (3m)-60%
Revenue NQ rev (1m)2.93%
Revenue NQ rev (3m)-10.45%
Revenue NY rev (1m)-3.84%
Revenue NY rev (3m)-3.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.91
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.97
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-2.51
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS3.66
BVpS5.54
TBVpS3.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.09%
ROE -67.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.96%
FCFM N/A
ROA(3y)-15.86%
ROA(5y)-8.2%
ROE(3y)-23.48%
ROE(5y)-12.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.28%
GM growth 5Y0.74%
F-Score2
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.77%
Cap/Sales 0.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.38
Altman-Z 0.32
F-Score2
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)9.51%
Cap/Depr(5y)15.03%
Cap/Sales(3y)0.3%
Cap/Sales(5y)0.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-462.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
EPS Next Y-39.4%
EPS Next 2Y25.42%
EPS Next 3Y26.51%
EPS Next 5YN/A
Revenue 1Y (TTM)8.72%
Revenue growth 3Y-5.29%
Revenue growth 5Y-2.73%
Sales Q2Q%7.58%
Revenue Next Year17.79%
Revenue Next 2Y27.22%
Revenue Next 3Y27.17%
Revenue Next 5Y-2.33%
EBIT growth 1Y-271.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-579.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-594.56%
OCF growth 3YN/A
OCF growth 5YN/A

VANDA PHARMACEUTICALS INC / VNDA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VANDA PHARMACEUTICALS INC (VNDA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VNDA.


What is the valuation status for VNDA stock?

ChartMill assigns a valuation rating of 1 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.


How profitable is VANDA PHARMACEUTICALS INC (VNDA) stock?

VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 2 / 10.


What is the expected EPS growth for VANDA PHARMACEUTICALS INC (VNDA) stock?

The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to decline by -39.4% in the next year.